IngredientesAescin is the major active principle from the horse chestnut tree (Aesculus hippocastanum L.) and is claimed to have clinical activity in venous insufficiency. The compound is known interchangeably as aescin and escin, the latter being the spelling more commonly used in pharmaceutical and European regulatory literature. Escin (polyhydroxyolean-12-ene 3-O-monodesmosides) is a natural mixture of triterpenoid saponins and occurs in either the alpha or beta form, which can be differentiated based on the water solubility and melting point, specific rotation, and hemolytic index.
The saponin aescin, a mixture of triterpenoid saponins, is obtained from the seeds of the horse chestnut tree Aesculus hippocastanum. The horse chestnut tree, Aesculus hippocastanum, whilst native to countries of the Balkan Peninsula, is also grown all around the world due to its beauty and high tolerability to harsh environmental conditions. The ingredient that is commonly cited as important in therapeutic outcomes is a mixture of triterpene saponins called aescin (syn. escin), which is extracted from the mature seeds of A. hippocastanum L. The plant belongs to the family Sapindaceae (formerly Hippocastanaceae). Related species whose seeds contain aescin-type saponins include Aesculus californica Nutt. (California buckeye), Aesculus glabra Willd. (Ohio buckeye), and Aesculus turbinata Blume (Japanese horse chestnut).
Aescin is a complex mixture of triterpene saponins. It consists of a water-soluble fraction (alpha-aescin) and a water-insoluble fraction (beta-aescin). The aescin molecule is constituted of a large and well-defined head group made of one glucuronic acid and two glucose molecules linked to a lipophilic sapogenin. The aglycones of aescin are derivatives of proto-ascigenin, acylated by acetic acid at C-22 and by either angelic or tiglic acids at C-21. The principal extract and medicinal constituent of Aesculus hippocastanum seeds is aescin, a mixture of triterpenoid saponin glycosides. Its components include glycosides of protoaescigenin and barringtogenol.
The main active constituents isolated from horse chestnut are aescin (approximately 10%) and prosapogenin. Aescin (escin) is a mix of the triterpene saponins alpha- and beta-aescin and cryptoaescin. β-escin is the more active constituent and is the form found in pharmaceutical products today. Within the aescin mixture, the fraction of C22-O-acetyl saponins, which are known as β-aescin, is considered more important in therapeutic effects.
A number of other products have been isolated from chestnut seeds, including coumarin derivatives (aesculin, fraxin, scopolin), essential oils (oleic acid, linoleic acid), and tannins (leucocyanidine, proanthocyanidin A2). The horse chestnut seed extract consists of escin, bioflavonoids such as quercetin and kaempherol, antioxidants such as proanthocyanidin A2, and the coumarins fraxin and esculin. Out of all of these, escin is the main contributor to the therapeutic effects observed from this extract.
Standardized horse chestnut seed extract (typically standardized to 16–20% aescin) is taken orally in capsule or tablet form, or used topically in creams or gels to reduce swelling and support vascular tone. Available preparations include standardized (aescin) dry extracts in tablets, capsules, and ointments; standardized (aescin) alcoholic extracts in drops and other liquids; and standardized (aescin) liquid extracts in drops and emulsions. In clinical and hospital settings, particularly in China and parts of Eastern Europe, sodium aescinate is available as an intravenous formulation for acute edema conditions. Commercially, the aescin molecule is modified to allow uptake from the gastrointestinal tract.
The horse chestnut is a deciduous tree that probably arrived in Central Europe from Turkey at the end of the 16th century, used as horse feed. Although the tree was introduced to Western Europe in the 16th century, medicinal uses of horse chestnut did not become widespread until the 19th century, when herbalists and physicians began using it for leg vein conditions and circulatory congestion.
In the past, the seed was used for different purposes, such as fever, in the 16th century, and hemorrhoid treatment in the early 19th century. Horse chestnut seeds have long been used in European phytotherapy to treat inflammatory and vascular problems. Earlier in traditional European folk medicine, the seeds and bark were used as remedies for rheumatism, fever, and bladder problems, though the raw seeds were often processed to reduce their toxic, bitter compounds.
Today, the horse chestnut seed extract is widely used in Europe and the USA in treatment of rheumatism, rectal complaints, bladder and gastrointestinal disorders, chronic venous insufficiency and post-operative edema. The use of Aesculus hippocastanum flower extract is described in traditional medicine for internal or external use, to treat venous inflammation, varicose veins, hemorrhoids and frostbite. The use of horse chestnut bark extracts is also known. Its bark, which has astringent properties, is used to combat diarrhea when taken orally and for antiseptic purposes when applied locally on wounds and ulcers.
In traditional Chinese medicine, escin is widely used for the treatment of cerebral edema and chronic venous insufficiency, among other conditions. Escin is the active component of Aesculus hippocastanum, the horse chestnut, which was itself used as a traditional medicine for centuries, and is still used to treat certain conditions, including hemorrhoids, varicose veins, hematoma, and venous congestion. Escin was first isolated in 1953.
According to the EMEA Committee on Herbal Medicinal Products' Assessment Report on Aesculus hippocastanum L. semen (2009), β-aescin has become particularly well-established in ethnopharmacological tradition because of its anti-edematous, anti-inflammatory and venotonic properties. The β-form is haemolytically active. The haemolytic activity results from the ability of aescin to form strong complexes with cholesterol in the red blood cell membrane. Because of this haemolytic activity, β-aescin is not administered intravenously in its pure form; pharmaceutical IV preparations use the sodium salt (sodium aescinate) which reduces this risk.
Aescin, the active principle of Aesculus hippocastanum, increases the tension of isolated human saphenous veins and rabbit portal veins. This effect, which is abolished by non-steroidal anti-inflammatory drugs, is due to preferential formation of PGF2α in the venous tissue. The increase in venous tone has been observed in different models and prostaglandin F2α (PGF2α) is a possible mediator of this process.
The therapeutic benefit is well supported by a number of experimental investigations in different animal models, indicative of clear-cut anti-oedematous, anti-inflammatory and venotonic properties, mainly related to the molecular mechanism of the agent, allowing improved entry of ions into channels, thus raising venous tension in both in vitro and in vivo conditions. Other mechanisms — release of PGF2 from veins, antagonism to 5-HT and histamine, reduced catabolism of tissue mucopolysaccharides — further underline the wide-ranging mechanisms of the therapeutic activity of aescin.
Escin produces a selective sensitization of vascular smooth muscles to calcium ions and reduces capillary permeability antagonizing the action of bradykinin, providing antiedematous and venotonic effects. In vitro studies have shown that HCSE induces contraction of isolated vein, which is thought to be mediated through 5-HT2A receptors.
The anti-inflammatory and anti-edematous effects of escin are related to the inhibition of the protein nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and hyaluronidase, as well as an increase in the glucocorticoid receptor. Escin improves capillary stability and inhibits hyaluronidase. Escin stimulates release of PGF2α leading to an anti-exudative effect through downregulation of inflammatory genes and upregulation of GM-CSF. PGF2α inhibits catabolism of venous tissue mucopolysaccharides and improves venous contractility.
Aescin inhibits proteolytic enzymes that induce leukocyte activation and also decreases capillary and venous permeability and increases venous tone. The anti-inflammatory effect of escin correlates with an elevation in the expression level of glucocorticoid receptor (GR) protein. Glucocorticoids exert anti-inflammatory effects by binding to GRs, which, upon activation, translocate to the nucleus and inhibit proinflammatory transcription factors, such as NF-κB.
In endothelial cells, β-escin potently induces cholesterol synthesis which is rapidly followed with a marked fall in actin cytoskeleton integrity. The concomitant changes in cell functioning result in a significantly diminished response to TNF-α stimulation. Aescin reduces capillary fragility by inhibiting the hyaluronidase enzyme.
Summary of Evidence: This is the best-studied indication for aescin and the one with the strongest clinical evidence base. A seed extract of horse chestnut (Aesculus hippocastanum L.) is a herbal remedy used for venous insufficiency. Seventeen randomised controlled trials were included in the Cochrane review. In all trials the extract was standardised to escin, which is the main active constituent of horse chestnut seed extract. Overall, the trials suggested an improvement in the symptoms of leg pain, oedema and pruritus with horse chestnut seed extract when taken as capsules over two to 16 weeks.
Overall, there appeared to be an improvement in CVI-related signs and symptoms with HCSE compared with placebo. Leg pain was assessed in seven placebo-controlled trials; six reported a significant reduction of leg pain in the HCSE groups compared to placebo. The superiority of HCSE is suggested by all placebo-controlled studies. The use of HCSE is associated with a decrease of the lower-leg volume and a reduction in leg circumference at the calf and ankle.
The extract from horse chestnut seeds, standardised for the content of aescin, is used as treatment for chronic venous insufficiency. It has anti-inflammatory and anti-oedematous properties and indicates a positive effect on the venous tone, rheological properties, and blood coagulability. The mechanism of HCSE/aescin activity was proposed on the basis of in vitro and in vivo studies, and its effectiveness was documented with numerous randomised clinical trials. The results of the studies have proven that horse chestnut seed extract not only significantly improves subjective symptoms in patients with chronic venous insufficiency like calf spasm, leg pain, pruritus, fatigue, but it also reduced leg volume, the ankle and calf circumference.
Comparison with compression therapy: Aescin has shown satisfactory evidence for a clinically significant activity in chronic venous insufficiency (CVI), haemorrhoids and post-operative oedema. In one controlled trial aescin was shown to be as effective as compression therapy as an alternative to medical treatment for CVI.
Limitations: More controlled clinical trials are needed, which should include larger numbers of participants and assess HCSE particularly for long-term use and as an adjunct to compression treatment. Many of the included trials in the Cochrane review had limitations in reporting of randomisation and blinding procedures, and most were of short duration (2–16 weeks).
Aescin has shown satisfactory evidence for a clinically significant activity in chronic venous insufficiency (CVI), haemorrhoids and post-operative oedema. In two clinical trials, 125 patients who received escin injections (5–10 mg twice a day) after surgery noticed reduced temperature and swelling 3–4 days after surgery. In one study, 85% of patients developed peri-orbital oedema after septorhinoplasty, of which 73% resolved on the first post-operative day with the use of Aescin (Reparil 40 mg tablet). The conclusion was that Aescin Diethylamine Salicylate can effectively reduce peri-orbital oedema following septorhinoplasty.
Evidence strength: Evidence for post-operative and post-traumatic oedema comes largely from older, smaller trials, many of which are not available in modern databases. The quality of evidence is generally considered preliminary to moderate.
Escin has been traditionally used to treat conditions such as chronic venous insufficiency, hemorrhoids, inflammation, and cerebral ischemic damage. Hemorrhoidal disease affects over 20% of the population. While treatments like Micronized Purified Flavonoid Fraction (MPFF) show promise, Aescin's efficacy remains uncertain. A registered clinical trial assessed the combined effectiveness of Aescin with MPFF against MPFF alone in treating hemorrhoids. Evidence for aescin specifically in haemorrhoids is less robust than for CVI; most data derive from older trials and current research is ongoing.
Treatment with escin decreases the TNF-α and brain water levels and alleviates histopathological changes associated with the permeability of the blood-brain barrier. Studies demonstrate that escin exerts neuroprotective effects in the middle cerebral artery occlusion rat model by reducing the migration of neutrophils and decreasing the protein expression of adhesion molecules (intercellular adhesion molecule-1 and E-selectin).
Aescin, a natural compound isolated from the seed of the horse chestnut, has been demonstrated to have anti-inflammatory and antiedematous effects. Studies have investigated whether aescin could induce protective effects against ischemia-reperfusion injury. Aescin, which worked in a dose-dependent manner, could significantly attenuate neuronal death and reduce lactate dehydrogenase (LDH) release after oxygen-glucose deprivation and simulated reperfusion. Aescin treatment at a concentration of 50 μg/ml provided protection with fewer side effects. Results showed that aescin upregulated the phosphorylation level of PRAS40 and proteins in the mTOR signaling pathway.
Evidence strength: Evidence for neuroprotection is predominantly from preclinical (animal and cell culture) studies. Clinical evidence in humans remains limited. In China, sodium aescinate is used clinically for cerebral oedema, but robust RCT data in this indication are sparse.
Escin reduced cell proliferation and induces apoptosis on glioma and lung adenocarcinoma cell lines. Escin suppressed the metastasis of triple-negative breast cancer cells through inhibiting epithelial-mesenchymal transition. Many recent studies showed escin might have antitumor effects in various cancer types. One clinical study was conducted to investigate the antitumor effect of escin on patients with advanced thyroid cancer — described as the first such clinical study. Escin showed striking effects on prolonging the progression-free survival and overall survival in those patients. The antitumor effect observed is consistent with other in vitro and in vivo studies showing escin has antitumor effects on lung cancer, breast cancer, liver cancer, pancreas cancer, and colon cancer. The dosage of escin used in the clinical study was 0.6 mg/kg/day intravenously for 9 days.
Evidence strength: Antitumor evidence is largely preclinical (in vitro and animal models). The thyroid cancer clinical report cited above is a single, early-phase clinical study with a small patient population. This area remains highly preliminary and is not an established clinical application.
A study tested the protective effect of aescin against the development of benign prostatic hyperplasia (BPH) in rats. Male Wistar rats were divided into control, BPH (testosterone oenanthate 3 mg/kg, s.c.), and BPH-aescin (testosterone oenanthate + aescin 10 mg/kg/day, p.o.) groups, with all treatments continuing for 4 weeks. Concurrent treatment with aescin decreased the testosterone-induced increase in prostatic IL-1β, TNF-α, and COX-2 expression by 47.9%, 71.2%, and 64.4%, respectively. This is an animal study only; no human clinical data in BPH are currently available.
Other investigations focus on the role of the major component aescin in male fertility, antiobesity, and anti-inflammatory effects. Aescin gel has been evaluated for use in bruising. Lab studies suggest that aescin, or escin, in horse chestnut has anti-inflammatory, neuroprotective, and antitumor effects, and may enhance gemcitabine efficacy. Evidence for male fertility, anti-obesity, and bruising reduction is preliminary and based primarily on small or preclinical studies.
In horse chestnut seed extracts (HCSE), the triterpene saponin mixture aescin is considered the active principle. The bioavailability and pharmacokinetics of different HCSE preparations have been studied under single and repeated applications using a radioimmunological method (RIA) developed to identify beta-aescin, one of the pharmacologically active fractions of the saponin mixture.
The bioavailability of β-aescin — the main active constituent of horse chestnut seed extract — in a non-retarded test medication in comparison with that in a retarded reference formulation was evaluated in two randomized crossover clinical trials involving 18 healthy volunteers each. Test and reference preparations demonstrated bioequivalence with regard to the extent of absorption; for the AUC (0–24 h post-administration), the 90% confidence interval ranged from 84% to 114% (point estimate: 98%). The differences observed for rate parameters can be disregarded due to the generally slow elimination and the wide therapeutic concentration range of escin.
In studies where procedures were identical, the pharmacokinetic data of beta-aescin show high variations. Even under steady-state conditions, a considerable variability for the same HCSE product is obtained. Escin serum concentrations were generally lower during the second dosing interval (night) than during the first interval, probably indicating a drug-by-food interaction. The morning dose was given after overnight fasting whereas the evening dose was given between meals.
For years, escin has been proven to be highly bioavailable, non-toxic, safe, and well-tolerated under oral ingestion.
Studies have commonly used doses of 300 mg of horse chestnut extract once or twice daily. This dose is usually equivalent to 50 mg of aescin. It has also been used topically (applied to the affected areas on the skin), normally in concentrations of 1–2%.
In the Cochrane-reviewed CVI trials, overall, the trials assessed HCSE taken as capsules over two to 16 weeks. For post-operative oedema, in two clinical trials, 125 patients who received escin injections of 5–10 mg twice a day after surgery noticed reduced temperature and swelling 3–4 days after surgery. For the investigational oncology use, the dosage of escin used was 0.6 mg/kg/day intravenously for 9 days.
To guarantee the effect, horse chestnut seed preparations should only be used in the form of finished medicinal products standardized to triterpene saponins (aescin); the dosage can be found in the patient information leaflet.
A meta-analysis of studies using a range of oral escin preparations demonstrated that these products were well tolerated, with no severe adverse events reported. The pooled incidence of any adverse event was similar with escin (14.4%) and placebo (12.4%), and these events were mild and transient.
The adverse events reported (in 14 trials) were mild and infrequent. They included gastrointestinal complaints, dizziness, nausea, headache and pruritus, from six studies.
High intravenous doses (>510 μg/kg) or concurrent use of nephrotoxic drugs (e.g., aminoglycosides) increase renal risk (reported relative risk = 2.1). The proposed mechanism involves direct tubular epithelial damage and reduced renal perfusion. For patients with mild-to-moderate renal impairment (eGFR 30–89 mL/min/1.73 m²), dose reduction and renal monitoring are required. In elderly patients, there is a higher risk of acute kidney injury (reported odds ratio = 1.8) due to age-related renal decline, with a recommendation for a 30% dose reduction.
The β-form of aescin is haemolytically active. The haemolytic activity results from the ability of aescin to form strong complexes with cholesterol in the red blood cell membrane. Haemolytic anaemia is a rare risk, attributed to saponin-induced erythrocyte membrane destabilization, associated with prolonged high-dose intravenous use.
Anaphylaxis has been reported at an incidence of approximately 0.2%, described as IgE-mediated reactions. Aescin has been anecdotally implicated as a potential source of occupational asthma. A 51-year-old employee of a pharmaceutical company developed bronchial asthma while working with plant extracts. Specific inhalation challenge showed that aescin was the culprit.
Caution is warranted with anticoagulants (e.g., warfarin) due to synergistic bleeding risk. This includes people who take blood-thinners or anticoagulants such as aspirin, clopidogrel, dipyridamole, warfarin, or dabigatran.
Aescin can either inhibit or induce activities of CYP1A2, CYP2C9 and CYP3A4. Therefore, caution is needed when aescin is co-administered with some CYP1A2, CYP2C9 or CYP3A4 substrates in clinical practice, which may result in treatment failure and herb-drug interactions. Treatment with a single dose or multiple doses of aescin had inductive effects on rat CYP1A2, while CYP2C9 and CYP3A4 enzyme activities were inhibited. Aescin had no inductive or inhibitory effect on the activity of CYP2E1. These data are from animal (rat) studies; direct extrapolation to humans requires further clinical validation.
It is also thought that horse chestnut extract interferes with the regulation of glucose. People who are prone to low blood sugar levels, such as diabetics taking glucose-lowering medication, should take care with horse chestnut extract.
Following daily oral administration of HCSE to rats and rabbits at 100 and 300 mg/kg body weight, no significant effects compared to control animals were observed in teratogenicity studies. At 300 mg/kg body weight in rabbits, a significant reduction (p<0.001) in the mean weight of the foetuses was observed. Escin may transfer to breast milk; suspending breastfeeding or using alternatives is advised. Horse chestnut preparations should not be used during pregnancy and lactation without consulting a doctor, as no adequate safety studies are available.
The clinical symptoms of CVI are not relevant in children and adolescents. The use of horse chestnut seeds and horse chestnut bark is not recommended for children and adolescents under the age of 18. Pediatric use is limited to severe cerebral edema under strict monitoring, due to limited safety data.
Escin should not be confused with esculetin — the poisonous ingredient in non-processed horse chestnuts. The raw, unprocessed seeds of Aesculus hippocastanum are not safe for consumption; pharmaceutical preparations use processed and standardized extracts from which aesculin (a toxic coumarin) is removed or reduced to safe levels.
Condiciones de salud que Escina puede ayudar a apoyar.
Aescin (escin), the active saponin of horse chestnut, is a validated topical anti-cellulite ingredient reducing capillary pore diameter, edema, and inflammatory mediators. It is included in a double-blind, placebo-controlled RCT and a Cochrane-referenced meta-analysis confirmed horse chestnut extract reduced leg volume by 32.1 mL in venous edema directly relevant to cellulite.
Aescin is the primary active triterpene saponin extracted from horse chestnut seed and is the constituent responsible for its venoactive and circulatory effects. Clinical trials confirm its ability to improve venous tone, reduce capillary permeability, decrease leg oedema, and relieve symptoms of chronic venous insufficiency. It is recognised by the European Medicines Agency (EMA) and German Commission E for CVI.
Aescin is the active triterpenoid saponin from horse chestnut (Aesculus hippocastanum) with well-documented venotonic, anti-inflammatory, and anti-edematous properties. A double-blind, placebo-controlled RCT in 72 hemorrhoid patients showed improvement in 82% of aescin-treated subjects versus 32% with placebo. Reviews confirm clinical efficacy comparable to synthetic flavonoid therapies for reducing perianal edema and venous congestion.
Aescin is the primary active triterpene saponin from horse chestnut responsible for its venotonic, anti-edema, and lymphatic-support effects. It maintains capillary integrity by inhibiting elastase and hyaluronidase, reducing fluid leakage. Multiple RCTs and a Cochrane review confirm aescin-standardized horse chestnut seed extract efficacy in reducing leg edema, with a clinical lymphoscintigraphy trial demonstrating improved lymphatic drainage rates.
Aescin (escin), the principal saponin from horse chestnut seed, promotes lymphatic fluid return by increasing venous tone and has demonstrated lymphedema-relevant effects in animal and human studies. A 2024 PMC review confirmed escin promotes lymphatic return and helps remove metabolic waste around blood vessel walls. An animal study showed topical aescin reduced lymphedema tail volume and significantly increased lymphatic vessel count on LYVE-1 staining.
Aescin is the active saponin from horse chestnut seed and is one of the most clinically studied natural venoactive compounds. It promotes venous tone, reduces capillary permeability, and inhibits elastase and hyaluronidase to protect vein walls. Multiple RCTs and a Cochrane review support its use for chronic venous insufficiency, of which spider veins are an early manifestation. Typical oral dosing is 100–150 mg aescin per day.
Aescin (escin), the active saponin fraction of horse chestnut, has anti-inflammatory and anti-edematous properties and is widely used topically in Europe for acute sprains during sports events. Clinical and pharmacological data support its role in reducing swelling following trauma.
Aescin is the active saponin from horse chestnut seed (Aesculus hippocastanum) and is one of the best-evidenced herbal treatments for chronic venous insufficiency (CVI), a condition closely associated with varicose veins. A Cochrane review of 17 RCTs (n=1,580) found it reduced leg pain and ankle swelling comparably to compression stockings. Germany's Commission E approved it for CVI symptoms. It acts by increasing venous tone, reducing capillary permeability, and inhibiting proteolytic enzymes that damage vessel walls.
Sistemas corporales que Escina puede ayudar a apoyar.
Volver